(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 April 2006 (27.04.2006)

PCT

(10) International Publication Number
WO 2006/044958 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 25/00* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/US2005/037576

(22) International Filing Date: 19 October 2005 (19.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/620,060 19 October 2004 (19.10.2004) US
0519957.5 30 September 2005 (30.09.2005) GB

(71) Applicants *(for all designated States except US)*: **SB PHARMCO PUERTO RICO INC.**; The Prentice Hall Corp System, c/o FGR Corporate Services, Inc., BBV Tower, 8th Floor, 254 Munoz Rivera Avenue, San Juan Puerto Rico 00918 (PR). **NEUROCRINE BIOSCIENCES INC.** [US/US]; 2790 El Camino Real, San Diego, CA 92130 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LANIER, Marion** [US/US]; c/o Neurocrine Biosciences Inc., 2790 El Camino Real, San Diego, CA 92130 (US). **LUO, Zhiyong** [CN/US]; c/o Neurocrine Biosciences Inc., 2790 El Camino Real, San Diego, CA 92130 (US). **MOORJANI, Manisha** [CA/US]; c/o Neurocrine Biosciences Inc., 2790 El Camino Real, San Diego, CA 92130 (US). **TELLEW, John, Edward** [US/US]; c/o Neurocrine Biosciences Inc., 2790 El Camino Real, San Diego, CA 92130 (US). **WILLIAMS, John, P.** [US/US]; c/o Neurocrine Biosciences Inc., 2790 El Camino Real, San Diego, CA 92130 (US). **ZHANG, Xiaohu** [CN/US]; c/o Neurocrine Biosciences Inc., 2790 El Camino Real, San Diego, CA 92130 (US).

(74) Agents: **MADDEN, Laura, K.** et al.; GlaxoSmithKline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O.Box 1539, King of Prussia, PA 19406-0939 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

[Continued on next page]

(54) Title: PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS



(I)

(57) Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R_1, R_{2a}, R_{2b}, Y, Het, *n*, o, R_6, Ar and R_7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

WO 2006/044958 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.